GlassScriptPhysician profile
Andrew M Pratt
NPI 1265860159
$86,608.88
in general payments reported to CMS, 2019-2025
7 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.04 · 2022: $31.57 · 2023: $20.72 · 2024: $34K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $11K · Travel and Lodging: $7,386 · Food and Beverage: $3,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,504.00 |
| Consulting Fee | $11,250.00 |
| Travel and Lodging | $7,385.81 |
| Food and Beverage | $3,418.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $86,443.40 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $42.38 | 2025 | Rexulti |
| Alkermes, INC. | $36.97 | 2025 | Aristada, Aristada Initio |
| Janssen Scientific Affairs, LLC | $31.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.72 | 2023 | Austedo Xr |
| Abbvie INC. | $19.04 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.80 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.